Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 124CNS 57Other hematologic neoplasm 38Sarcoma 34Plasma cell 22Dermatologic 10Myeloid 5Breast 5Genitourinary 3Gastrointestinal 3Other solid neoplasm 2Classical hematology 2Tumor-Agnostic 1Head & Neck 1Gynecologic 1

Conditions

Neoplasm, Residual 1

Interventions

pembrolizumab 94Paclitaxel 85Gemcitabine 83Carboplatin 79Docetaxel 60Cisplatin 58Bevacizumab 58Nivolumab 56Fluorouracil 47Capecitabine 46Magnetic Resonance Spectroscopy 44Radiotherapy 41Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 37Pemetrexed 34Leucovorin 34Biopsy 34atezolizumab 33Cetuximab 32Standard of Care 31Trastuzumab 28Cyclophosphamide 28Blood Specimen Collection 28Radiosurgery 27Specimen Handling 26Sorafenib 26Ipilimumab 26Everolimus 26olaparib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carmustine × Tumor-Agnostic × Clear all
NCT02670109 2020-01-14

Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment for Triple Negative Breast Cancer Patients

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

Phase 2 Unknown
20 enrolled
Tumor-Agnostic

Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡